Abstract：At present, immunological checkpoint inhibtors (ICPIs) is one of the important choices for the treatment of malignant tumors after radiotherapy and chemotherapy. It has achieved good therapeutic effects in the treatment of various solid tumors. However, these drugs can also produce a wide range of immune-related adverse events (irAEs), affecting patients′ life quality and prognosis. Therefore, nurses as the main point of contact for immunotherapy patients need to fully understand irAEs and their appropriate treatment strategies to improve the prognosis and quality of life of patients treated with ICPIs. This article reviews the progress of adverse reactions in the treatment of tumor immunological checkpoint inhibitors and its monitoring and treatment strategies.
[1] D′Angelo SP，Larkin J，Sosman JA，et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma：A Pooled Analysis [J]. J Clin Oncol，2017，35（2）：226-235.
[2] Raedler LA. Opdivo（Nivolumab）：Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Me-lanoma [J]. Am Health Drug Benefits，2015，8（Spec Feature）：180-183.
[3] Khoja L，Butler MO，Kang SP，et al. Pembrolizumab [J]. J Immunother Cancer，2015，3（1）：36.
[4] Kythreotou A，Siddique A，Mauri FA，et al. PD-L1 [J]. J Clin Pathol，2017（12）：189-194.
[5] Inman BA，Longo TA，Ramalingam S，et al. Atezolizumab：a PD-L1 blocking antibody for bladder cancer [J]. Clin Cancer Res，2017，23（8）：1886-1890.
[6] Massard C，Gordon MS，Sharma S，et al. Safety and Efficacy of Durvalumab （MEDI4736），an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor，in Patients With Advanced Urothelial Bladder Cancer [J]. J Clin Oncol，2016，34（26）：3119-3125.
[7] Angell TE，Min L，Wieczorek TJ，et al. Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma [J]. Genes Dis，2017，5（1）：46-48.
[8] Motzer RJ，Tannir NM，Mcdermott DF，et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J]. N Engl J Med，2018，378（14）：1277-1290.
[9] Weber JS，Postow M，Lao CD，et al. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents [J]. Oncologist，2016，21（10）：1230-1240.
[10] Weber JS，K?覿hler KC，Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab [J]. J Clin Oncol，2012，30（21）：2691-2697.
[11] Boutros C，Tarhini A，Routier E，et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [J]. Nat Rev Clin Oncol，2016，13（8）：473-486.
[12] Villadolid J，Amin A. Immune checkpoint inhibitors in clinical practice： update on management of immune-related toxicities [J]. Transl Lung Cancer Res，2015，4（5）：560-575.
[13] Antonia SJ，Villegas A，Daniel D，et al. Durvalumab after Chemoradiotherapy in Stage Ⅲ Non-Small-Cell Lung Cancer [J]. N Engl J Med，2017，377（20）：1919-1929.
[14] Teulings HE，Limpens J，Jansen SN，et al. Vitiligo-like depigmentation in patients with stage Ⅲ-Ⅳ melanoma receiving immunotherapy and its association with survival：a systematic review and meta-analysis [J]. J Clin Oncol，2015，33（7）：773-781.
[15] Belum VR，Benhuri B，Postow MA，et al. Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor [J]. Eur J Cancer，2016，60：12-25.
[16] Davies M，Duffield EA. Safety of checkpoint inhibitors for cancer treatment：strategies for patient monitoring and management of immune-mediated adverse events [J]. Immunotargets Ther，2017，6：51-71.
[17] Rittmeyer A，Barlesi F，Waterkamp D，et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer （OAK）：a phase 3，open-label，multicentre randomised controlled trial [J]. Lancet，2016，389（10 066）：255-265.
[18] Carbone DP，Reck M，Paz-Ares L，et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J]. N Engl J Med，2017，39（25）：2415-2426.
[19] Eggermont AM，Chiarionsileni V，Grob JJ，et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage Ⅲ melanoma（EORTC 18071）：a randomised，double-blind，phase 3 trial [J]. Lancet Oncol，2015， 16（5）：522-530.
[20] Haanen J，Carbonnel F，Robert C，et al. Management of toxicities from immunotherapy：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up [J]. Ann Oncol，2017，28（suppl_4）：iv119-iv142.
[21] Ryder M，Callahan M，Postow MA，et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma：a comprehensive retrospective review from a single institution [J]. Endocr Relat Cancer，2014，21（2）：371-381.
[22] Iwama S，De RA，Callahan MK，et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody [J]. Sci Transl Med，2014，6（230）：230-245.
[23] Weber JS，D′Angelo SP，Minor D，et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment（CheckMate 037）：a randomised，controlled，open-label，phase 3 trial [J]. Lancet Oncol，2015，16（4）：375-384.
[24] Barbee MS，Ogunniyi A，Horvat TZ，et al. Current status and future directions of the immune checkpoint inhibitors ipilimumab，pembrolizumab，and nivolumab in oncology [J]. Ann Pharmacother，2015，49（8）：907.
[25] Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist [J]. Am Soc Clin Oncol Educ Book，2012，32：174-177.
[26] Ledezma B，Heng A. Real-world impact of education：treating patients with ipilimumab in a community practice setting [J]. Cancer Manag Res，2013，6：5-14.
[27] Weber J，Gibney G，Kudchadkar RR，et al. Phase Ⅰ/Ⅱ study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab [J]. Cancer Immunol Res，2016，4（4）：345.
[28] Sosa A，Cadena EL，Olive CS，et al. Clinical assessment of immune-related adverse events [J]. Ther Adv Med Oncol，2018，10：3861-3966.
2019, Vol. 16 
京公网安备 11010502046598号